IoT

Search documents
SHAREHOLDER ALERT: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Class Action Lawsuit Deadline
Prnewswire· 2025-07-21 20:06
PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") on behalf of investors who suffered losses due to alleged material misstatements and omissions.If you purchased Rocket Pharmaceuticals stock during the period from September 17, 2024 to May 26, 2025 (the "Class Period"), you m ...
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
Prnewswire· 2025-07-21 20:05
CARLSBAD, Calif., July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25, 2025. Details of the event are below: Title: "Fireside Chat on Achondroplasia and Growth Dis ...
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
Prnewswire· 2025-07-21 20:02
NEW YORK, July 21, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2025.So What: If you purchased Biohaven securities during the Class Period you may ...
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
GlobeNewswire News Room· 2025-07-21 19:59
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating iTeos Therapeutics, Inc. (NASDAQ: ITOS) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transact ...
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets
Benzinga· 2025-07-21 19:06
On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s SRPT investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.The decision stemmed from serious safety concerns, including three patient deaths potentially linked to these products, indicating that study participants faced or would be exposed to an unreasonable and significant risk of illness or injury.The FDA also formally requested Sarepta to voluntarily halt all shipments o ...
X @Elon Musk
Elon Musk· 2025-07-21 17:22
Neuralink will do live-changing good for ultimately millions, maybe billions, of people.Imagine your loved one being able to walk again or your parent with dementia being able to recognize their child again.Neuralink (@neuralink):We successfully completed both P8 and P9 this weekend, our first time performing two surgeries in one day. Both participants are recovering well and in great spirits. We are looking forward to supporting them on their Neuralink journey. ...
Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rally
Proactiveinvestors NA· 2025-07-21 16:52
Core Insights - Mesoblast Ltd's shares surged nearly 38% following the successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, with gross revenue of US$13.2 million reported for the first quarter post-launch [1][2] Financial Performance - The company reported a strong financial foundation with US$162 million (A$247 million) in cash at the end of the quarter, positioning it for continued expansion [3] - Mesoblast received US$1.6 million in royalties from the sale of TEMCELL® HS Inj. in Japan through its licensing agreement [3] Regulatory Exclusivity - Ryoncil® received seven years of orphan-drug exclusivity from the FDA for SR-aGvHD in pediatric patients, protecting it from competition in the US market during that period [4] - The company holds biologic exclusivity preventing competitors from referencing Ryoncil®'s biologic license application (BLA) until December 2036, effectively barring biosimilars from entering the market for more than a decade [4] Commercial Launch and Market Coverage - The company has onboarded more than 25 transplant centers, with plans to complete onboarding at 45 priority centers this quarter [6] - Ryoncil® is now insured for more than 250 million US lives through both commercial and government payers, including federal Medicaid, effective from July 1 [6] Future Expansion Plans - Mesoblast is focused on expanding the use of Ryoncil® in adults with SR-aGvHD and has met with the FDA to discuss a pivotal trial for this population [7] - The company is also advancing its second-generation allogeneic MSC therapy, rexlemestrocel-L, for chronic inflammatory diseases, with recent meetings aligning the company and regulators on the pathway to filing for biologics license approval (BLA) [8] Market Reaction - Despite a promising week, investor sentiment has moderated, with shares trading at A$2.32, down 3.73% from Friday highs [9] - The company's long-term prospects remain strong, supported by Ryoncil®'s commercial launch and a robust cash position as it enters the next growth phase [9][10]
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of August 8, 2025 Lead Plaintiff Deadline in the PepGen Inc. (PEPG) Class Action – Investors With Significant Losses Encouraged to Contact the Firm
GlobeNewswire News Room· 2025-07-21 16:08
ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about PepGen’s business, operations, and prospects, including allegations that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was deficient for pur ...
CARBIOS enters the r-PET market for tire textile filaments
Globenewswire· 2025-07-21 15:45
CARBIOS has signed a multi-year commercial agreement with Indorama Ventures, the world leader in polyester production. CARBIOS will supply recycled monomers that will be transformed into filaments by Indorama Ventures, intended for use in tire reinforcement for Michelin.This new commercial agreement highlights the interest of a new market—industrial fabrics—for high-quality r-PET derived from enzymatic recycling. Clermont-Ferrand (France), 21 July 2025 (17h45 CEST) – CARBIOS (Euronext Growth Paris: ALCRB) ...
3 Bullish Biotech Stocks With Explosive Growth Trends
MarketBeat· 2025-07-21 15:03
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement. This is particularly true of small-cap biotech stocks. In many cases, these are unprofitable companies with little to no revenue. However, these are also the companies that can provide the highest return for risk-tolerant investors. The risk with these stocks is that the company can deliver poor clinica ...